Michael Ryskin
Stock Analyst at B of A Securities
(1.37)
# 3,476
Out of 4,915 analysts
37
Total ratings
47.83%
Success rate
-3.46%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $68 → $70 | $56.59 | +23.70% | 6 | Jun 25, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $535 → $475 | $534.31 | -11.10% | 3 | Apr 21, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.34 | +241.88% | 3 | Mar 3, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $129.01 | +59.68% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $40.98 | -2.39% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.36 | +77.24% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $9.84 | +143.90% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.44 | +78.57% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $145.79 | +23.47% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.95 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $20.33 | +155.78% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.83 | +253.36% | 2 | Nov 10, 2021 |
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68 → $70
Current: $56.59
Upside: +23.70%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535 → $475
Current: $534.31
Upside: -11.10%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.34
Upside: +241.88%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $129.01
Upside: +59.68%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $40.98
Upside: -2.39%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.36
Upside: +77.24%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $9.84
Upside: +143.90%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.44
Upside: +78.57%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $145.79
Upside: +23.47%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.95
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $20.33
Upside: +155.78%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.83
Upside: +253.36%